Abstract: A method of reducing the incidence of mucocutaneous ulcers or vasculitis in an individual comprising administering an effective amount of dusquetide in a formulation, wherein the formulation comprises no excipients. More specifically, a method of treating oral, genital or cutaneous aphthous lesions in an individual by administering an effective amount of excipient-free dusquetide, wherein the individual has been diagnosed with Behçet's disease.

Abstract: A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.

Abstract: Methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.

Abstract: Improved systems and methods for producing synthetic hypericin at high volume and high purity. In particular, systems and methods of preparing a purified synthetic hypericin resulting from irradiation, wherein the irradiation step is performed in a continuous flow micro-reactor. The process of manufacturing purified synthetic hypericin results in the synthetic yield of 30-100% of the dry product.

Abstract: Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual.

Abstract: Improved systems and methods for producing synthetic hypericin at high volume and high purity.

Abstract: Improved systems and methods for producing synthetic hypericin at high volume and high purity.

Abstract: Methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.

Abstract: Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual.

Abstract: Improved systems and methods for producing synthetic hypericin at high volume and high purity.

Abstract: Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual.

Abstract: Innate Defense Regulators (IDRs) interact with intracellular signaling events and modulate the innate defense response. Whereas much of the initial work with the IDRs focused on their role in fighting infection, recent results in animal models of chemotherapy- or radiation-induced mucositis and wound healing suggest that IDRs can be beneficial during the responses to a broader range of damage-inducing agents beyond pathogens. RIVPA (SEQ ID NO. 5), has demonstrated safety in humans and efficacy in animal models of fractionated radiation-induced and chemotherapy-induced oral mucositis, in models of chemotherapy induced damage to the gastro-intestinal tract and in models of local and systemic Gram-positive and Gram-negative infection in immunocompetent and immunocompromised hosts. Based on this information, we propose the use of RIVPA (SEQ ID NO. 5) and/or other IDRs (Table 1) as a novel treatment for Macrophage Activation Syndrome.

Abstract: Results from two randomized trials have shown that oral beclomethasone dipropionate (BDP) is effective for treatment of acute gastrointestinal graft-versus-host disease (GVHD). Here, we report results of a double-blind, randomized placebo-controlled phase II study designed to test the hypothesis that acute GVHD could be prevented by administration of oral BDP, beginning before hematopoietic cell transplantation (HCT) and continuing until day 75 after HCT. Study drug (BDP or placebo) was administered as 1 mg immediate-release formulation plus 1 mg delayed-release formulation orally four times daily. According to the primary endpoint, systemic glucocorticoid treatment for GVHD was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of 46 participants (67%) in the placebo arm. The secondary efficacy endpoints showed no statistically significant differences between the two arms.

Abstract: Regimens for the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia are disclosed.

Abstract: Regimens for the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia are disclosed.